P. Schmid says that for many years oncologists used single agent endocrine therapy and now there are substantial results for combination treatment with CDK4/6 inhibitors in first-line metastatic breast cancer (mBC). However, the role for single agent endocrine therapy remains in cases of low disease activity, slow progressing disease, long disease-free interval. Long term outcome data with early use of CDK4/6 inhibitors are expected and it should be elucidated what happens to patients upon progression to CDK4/6 inhibition.

Oncology Meeting Resources

Major Sponsors

AstraZeneca Janssen Servier

Main Sponsors

Amgen Astellas Bayer Healthcare Boehringer Ingelheim Genomic Health Inc. ipsen Lilly Oncology MSD Nutricia Roche